Developer docs
API playgroundTry for free, no card

Search company profiles

Absci

Full company profile

uuid00000tg

Namestring
Absci
Legal namestring
Absci Corporation
Websiteurl
absci.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Absci is a publicly traded (NASDAQ: ABSI) generative AI drug creation company founded in 2011 and headquartered in Vancouver, Washington, with research facilities in New York, Belgrade, and Zug (Switzerland), and clinical operations in Sydney, Australia. The company's core offering is an Integrated Drug Creation Platform that combines proprietary synthetic biology (SoluPro), high-throughput wet-lab screening (ACE Assay, >4,000x traditional throughput), and generative AI models (Origin-1, AbsciGen comprising AbsciDiff and IgDesign2, and AbsciBind for scoring) in a 6-week Lab-in-the-Loop cycle. This platform is designed to enable de novo antibody design against undruggable and zero-prior epitopes, multiparametric lead optimization, and AI-enabled target discovery via Reverse Immunology, generating approximately 2.97 billion proprietary protein-protein interaction data points weekly to feed its models.

Absci operates a dual business model combining platform partnership revenue with internal pipeline development. Partnership revenue is generated through multi-year collaboration agreements with large pharmaceutical companies that include upfront payments, research funding, milestone payments, and royalties; notable deals include Merck ($610M potential value), AstraZeneca ($247M), and Almirall. The internal pipeline includes ABS-201, an AI-designed anti-prolactin receptor antibody in Phase 1/2a for androgenetic alopecia with Phase 2 in endometriosis planned for Q4 2026, and ABS-202 in preclinical development for an inflammation and immunology indication. Strategic compute partnerships with AMD, Oracle Cloud Infrastructure, and NVIDIA provide the underlying AI infrastructure. As of year-end 2025, Absci had ~$144.3M in cash supporting runway into H1 2028, FY2025 revenue of ~$2.8M, R&D expense of $81.4M, and a net loss of $115.2M, reflecting its pre-commercial clinical-stage status.

Short descriptiontext

Absci is a publicly traded generative AI drug creation company that combines proprietary synthetic biology and deep learning to design and validate novel biologic drug candidates, serving large pharmaceutical partners and advancing its own internal pipeline of AI-designed antibody therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersVancouver, United States
HQ citystring
Vancouver
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generative AI drug discovery, biologics design platform, antibody engineering, AI drug creation, de novo antibody design
Industry5 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI Drug Discovery Platform
Social media profiles4 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Partnership/Collaboration Revenue
TypeLicensing Royalties
Description

Absci generates revenue through strategic partnerships with pharmaceutical companies including upfront payments, research funding, milestone payments, and potential royalties. Examples include Merck ($610M biobucks deal) and AstraZeneca ($247M AI-enabled oncology pact).

fool.com
2Equity Financing
TypeTransaction Fee
Description

The company raised $100M in June 2026 underwritten offering with Eli Lilly investing $40M. Also maintains ATM (at-the-market) share issuance programs.

bitget.com
3Internal Pipeline Development
TypeLicensing Royalties
Description

Developing proprietary therapeutic candidates (ABS-201, ABS-202, ABS-101) with plans to commercialize independently or partner later-stage assets.

fool.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Partnership-based drug creation services
ModelOtherBilling cadenceMulti-year contract
Notes

Structured as custom deals with pharmaceutical partners including upfront payments, R&D funding, development milestones, and commercial royalties (e.g., Merck $610M potential, AstraZeneca $247M)

globenewswire.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Absci operates an Integrated Drug Creation Platform that combines generative AI models with proprietary high-throughput wet lab validation (SoluPro synthetic biology and ACE Assay) to enable de novo antibody design, multi-parametric lead optimization, and novel target discovery via reverse immunology. The platform serves pharmaceutical and biotech partners through drug creation collaborations structured with upfront payments, R&D funding, milestone payments, and royalties, while Absci simultaneously develops an internal pipeline of AI-designed therapeutics including ABS-201 (anti-PRLR antibody for androgenetic alopecia and endometriosis) and ABS-202.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • AI-designed antibodies validated from concept to clinical trial pipeline in ~24 months
+7 more records
Product overview1 text field

Absci is a generative AI drug creation company operating a unified Integrated Drug Creation Platform that combines high-throughput wet lab data generation (SoluPro, ACE Assay) with generative AI models (AbsciGen, AbsciBind) and multiparametric AI lead optimization. The platform enables de novo antibody design and novel target discovery via reverse immunology. Key pipeline products include ABS-201 (anti-PRLR antibody in Phase 1/2a for androgenetic alopecia and Phase 2 planning for endometriosis), ABS-202 (preclinical anti-PRLR for inflammation/I\&I), and internal/preclinical programs. The Origin-1 platform extends de novo capabilities to zero-prior epitopes. Absci partners with pharma companies (AstraZeneca, Merck, Almirall) and technology providers (Oracle, AMD, NVIDIA) to power its platform.

Product and service6 records
1Integrated Drug Creation Platform
CategoryAI Drug Creation Platform
Description

Absci's core AI-powered drug creation platform that integrates wet lab and AI in iterative cycles, enabling de novo design of biologics and multiparametric lead optimization. Processes high-throughput protein-protein interaction data (2.97+ billion data points weekly) to train generative AI models, create antibody designs in silico, and validate candidates in wet lab within six weeks. Sold to pharmaceutical partners via strategic collaborations.

2Origin-1
CategoryAI Drug Discovery Platform
Description

A generative AI platform for de novo design of full-length monoclonal antibodies against 'zero-prior' epitopes (target sites with no reported complex structures). Delivers specific, developable binders in fewer than 100 designs per target with atomic accuracy validated by cryo-EM. Uses AbsciGen (AbsciDiff + IgDesign2) as the generative engine and AbsciBind as the scoring/filtering engine.

3ABS-201 (Androgenetic Alopecia)
CategoryInternal Pipeline Therapeutic
Description

An AI-designed anti-prolactin receptor (PRLR) monoclonal antibody for the treatment of androgenetic alopecia (AGA). Demonstrated superior hair regrowth versus minoxidil in preclinical studies, with a Phase 1/2a HEADLINE trial initiated in December 2025. Estimated half-life of at least 65 days supports 2-3 doses over six months.

4ABS-201 (Endometriosis)
CategoryInternal Pipeline Therapeutic
Description

Indication expansion of ABS-201 anti-PRLR antibody for endometriosis as a non-sex-steroid hormonal therapeutic. Preclinical data demonstrated significant reductions in both spontaneous and evoked pain behaviors and suppression of inflammatory cytokines. Phase 2 trial targeted to initiate in Q4 2026.

5ABS-202
CategoryInternal Pipeline Therapeutic
Description

A second anti-PRLR antibody in preclinical development targeting an inflammation and immunology indication, announced in 2026 as part of Absci's expanded prolactin program portfolio.

6Reverse Immunology (AI Target Discovery)
CategoryAI Drug Discovery Service
Description

AI-enabled approach for novel therapeutic target discovery that identifies antibodies from patient samples of super immune responders, reconstructs fully human antibody sequences in silico, and pairs them with target antigens for AI optimization and IND-enabling studies.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Oracle Cloud Infrastructure
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-12
Description

Collaboration to accelerate generative AI-driven drug discovery using OCI AI infrastructure and AMD GPUs. Enables Absci to consolidate infrastructure, reduce inter-GPU latency to 2.5 microseconds, and scale large-scale molecular-dynamics simulations.

oracle.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-09-02
Description

Expanded collaboration to accelerate AI-powered drug discovery for skin diseases. Almirall's Karl Ziegelbauer stated: 'Almirall chose Absci because their de novo platform brings truly novel innovation to the industry's most challenging targets with high unmet medical need.'

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-08-12
Description

AI antibody generator collaboration for cancer research. Absci inks cancer collaboration with Memorial Sloan Kettering for AI-designed antibody therapeutics in oncology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-04
Description

$247M AI-enabled oncology antibody design pact. Absci applies its de novo AI antibody creation platform to design potential new antibody therapy in oncology. AstraZeneca's Puja Spara stated: 'This collaboration is an exciting opportunity to utilize Absci's de novo AI antibody creation platform to design a potential new antibody therapy in oncology.'

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-07
Description

$610M biobucks drug discovery partnership (potential milestones and royalties). Merck Global Health Innovation Fund's Prem Tumkosit noted Absci falls into 'Next Horizon' technologies with potential to disrupt biopharma industry.

Strategic tierCoreTypeTechnology or Integration
Description

AMD invested in Absci and partnered to scale AI drug discovery using AMD Instinct MI355X GPUs. Mark Papermaster (CTO at AMD) stated: 'We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics.'

Strategic tierMajorTypeTechnology or Integration
Description

NVIDIA powers Absci's in silico technologies. Kimberly Powell (VP Healthcare at NVIDIA) stated: 'Absci's powerful data generation and AI protein engineering platform is already helping the drug discovery industry, and NVIDIA is excited to help power and scale Absci's in silico technologies to achieve the best positive impact.'

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Co-development partnership for immuno-oncology candidates. Owkin's Thomas Clozel (CEO) stated: 'This partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin's AI agents that can identify and experimentally validate novel therapeutic targets with Absci's pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.'

Strategic tierMajorTypeStrategic or Co-development Partner
Description

R&D partnership combining leading generative AI approaches with PrecisionLife's unique disease biology insights. Steve Gardner (CEO of PrecisionLife) stated: 'Our partnership demonstrates the transformational innovation potential of coupling leading generative AI approaches with PrecisionLife's unique disease biology insights.'

Strategic tierMajorTypeStrategic or Co-development Partner
Description

HIV vaccine research collaboration funded by Bill & Melinda Gates Foundation. Absci designs antibody or antibody-like protein to bind to conserved HIV target exposed during cell infection process, in partnership with Caltech researchers.

11Invetx
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for innovative specialty therapeutics for companion animals. Juergen Horn (President of Invetx) stated: 'We selected Absci for this collaboration because of their leading platform for generative AI design of human antibodies.'

absci.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partnership for AI-driven biological research and antibody development

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Generate Biomedicines is a generative AI biology company designing de novo protein therapeutics, directly comparable to Absci's Origin-1 and Integrated Drug Creation Platform. Both compete for large-pharma partnership deals centered on AI-designed antibodies and novel biologics.

TypeDirect peer
Description

AbCellera is a public antibody discovery platform that combines high-throughput wet lab screening with machine learning to identify lead candidates for pharma partners. It competes head-to-head with Absci's SoluPro/ACE Assay stack and is similarly partnered with major pharmaceutical companies.

TypeDirect peer
Description

BigHat Biosciences uses AI/ML-guided antibody design with an integrated wet lab loop, mirroring Absci's lab-in-the-loop approach. Both target the same customer base (pharma seeking AI-designed antibody leads) and compete on cycle time, developability, and success rates.

TypeDirect peer
Description

Insilico Medicine operates an AI-driven drug discovery platform that combines generative chemistry, target identification, and clinical development. While broader in modality than Absci, it is a directly comparable AI biotech pursuing pharma partnerships and an internal pipeline.

5Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is Alphabet's commercial AI drug discovery business, applying DeepMind's protein-structure and generative modeling to pharma partnerships. As a deep-pocketed incumbent with overlapping capability to Absci's Origin-1, it is the most consequential broad competitor in the AI biologics design space.

TypeDirect peer
Description

Recursion is a publicly traded AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Like Absci, it pursues both a partnership model and an internal pipeline, and competes for similar pharma and investor mindshare.

TypeDirect peer
Description

Schrödinger provides computational chemistry and physics-based software for drug discovery, serving many of the same pharmaceutical customers as Absci. It is comparable as a public, platform-oriented AI-for-drug-discovery company monetized through software and partnerships.

TypeDirect peer
Description

Adimab operates a proprietary antibody discovery and optimization platform serving pharma and biotech partners. It is directly comparable to Absci's antibody discovery and lead-optimization offering and competes for similar partnership economics.

TypeEmerging player
Description

Cradle is an AI protein engineering platform that uses generative models to help partners design improved proteins, including antibodies and enzymes. It overlaps with Absci's generative biology capabilities and targets a similar partner base, with a narrower focus on protein design.

TypeEmerging player
Description

EvolutionaryScale is an AI protein design company developing frontier generative models for protein engineering. While earlier-stage and more research-oriented, it competes for the same AI-for-proteins narrative and could attract comparable pharma collaborations in the longer term.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors29 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Absci

AI Drug Discovery Platformabsci.com

Absci is a publicly traded generative AI drug creation company that combines proprietary synthetic biology and deep learning to design and validate novel biologic drug candidates, serving large pharmaceutical partners and advancing its own internal pipeline of AI-designed antibody therapeutics.

What Absci does

Absci is a publicly traded (NASDAQ: ABSI) generative AI drug creation company founded in 2011 and headquartered in Vancouver, Washington, with research facilities in New York, Belgrade, and Zug (Switzerland), and clinical operations in Sydney, Australia. The company's core offering is an Integrated Drug Creation Platform that combines proprietary synthetic biology (SoluPro), high-throughput wet-lab screening (ACE Assay, >4,000x traditional throughput), and generative AI models (Origin-1, AbsciGen comprising AbsciDiff and IgDesign2, and AbsciBind for scoring) in a 6-week Lab-in-the-Loop cycle. This platform is designed to enable de novo antibody design against undruggable and zero-prior epitopes, multiparametric lead optimization, and AI-enabled target discovery via Reverse Immunology, generating approximately 2.97 billion proprietary protein-protein interaction data points weekly to feed its models.

Absci operates a dual business model combining platform partnership revenue with internal pipeline development. Partnership revenue is generated through multi-year collaboration agreements with large pharmaceutical companies that include upfront payments, research funding, milestone payments, and royalties; notable deals include Merck ($610M potential value), AstraZeneca ($247M), and Almirall. The internal pipeline includes ABS-201, an AI-designed anti-prolactin receptor antibody in Phase 1/2a for androgenetic alopecia with Phase 2 in endometriosis planned for Q4 2026, and ABS-202 in preclinical development for an inflammation and immunology indication. Strategic compute partnerships with AMD, Oracle Cloud Infrastructure, and NVIDIA provide the underlying AI infrastructure. As of year-end 2025, Absci had ~$144.3M in cash supporting runway into H1 2028, FY2025 revenue of ~$2.8M, R&D expense of $81.4M, and a net loss of $115.2M, reflecting its pre-commercial clinical-stage status.

Absci firmographics

Firmographics
Name
Absci
Legal name
Absci Corporation
Website
https://absci.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
Absci is a publicly traded generative AI drug creation company that combines proprietary synthetic biology and deep learning to design and validate novel biologic drug candidates, serving large pharmaceutical partners and advancing its own internal pipeline of AI-designed antibody therapeutics.
Ownership category
akta.pro rank

Absci industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Generative AI drug discovery
  • Biologics design platform
  • Antibody engineering
  • AI drug creation
  • De novo antibody design

Where Absci is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Absci business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partnership/Collaboration Revenue: Absci generates revenue through strategic partnerships with pharmaceutical companies including upfront payments, research funding, milestone payments, and potential royalties. Examples include Merck ($610M biobucks deal) and AstraZeneca ($247M AI-enabled oncology pact).
  2. Equity Financing: The company raised $100M in June 2026 underwritten offering with Eli Lilly investing $40M. Also maintains ATM (at-the-market) share issuance programs.
  3. Internal Pipeline Development: Developing proprietary therapeutic candidates (ABS-201, ABS-202, ABS-101) with plans to commercialize independently or partner later-stage assets.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPartnership-based drug creation services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Absci product offering

Product offering

Core offering

Absci operates an Integrated Drug Creation Platform that combines generative AI models with proprietary high-throughput wet lab validation (SoluPro synthetic biology and ACE Assay) to enable de novo antibody design, multi-parametric lead optimization, and novel target discovery via reverse immunology. The platform serves pharmaceutical and biotech partners through drug creation collaborations structured with upfront payments, R&D funding, milestone payments, and royalties, while Absci simultaneously develops an internal pipeline of AI-designed therapeutics including ABS-201 (anti-PRLR antibody for androgenetic alopecia and endometriosis) and ABS-202.

Product overview

Absci is a generative AI drug creation company operating a unified Integrated Drug Creation Platform that combines high-throughput wet lab data generation (SoluPro, ACE Assay) with generative AI models (AbsciGen, AbsciBind) and multiparametric AI lead optimization. The platform enables de novo antibody design and novel target discovery via reverse immunology. Key pipeline products include ABS-201 (anti-PRLR antibody in Phase 1/2a for androgenetic alopecia and Phase 2 planning for endometriosis), ABS-202 (preclinical anti-PRLR for inflammation/I\&I), and internal/preclinical programs. The Origin-1 platform extends de novo capabilities to zero-prior epitopes. Absci partners with pharma companies (AstraZeneca, Merck, Almirall) and technology providers (Oracle, AMD, NVIDIA) to power its platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Integrated Drug Creation Platform Absci's core AI-powered drug creation platform that integrates wet lab and AI in iterative cycles, enabling de novo design of biologics and multiparametric lead optimization. Processes high-throughput protein-protein interaction data (2.97+ billion data points weekly) to train generative AI models, create antibody designs in silico, and validate candidates in wet lab within six weeks. Sold to pharmaceutical partners via strategic collaborations.
  • Origin-1 A generative AI platform for de novo design of full-length monoclonal antibodies against 'zero-prior' epitopes (target sites with no reported complex structures). Delivers specific, developable binders in fewer than 100 designs per target with atomic accuracy validated by cryo-EM. Uses AbsciGen (AbsciDiff + IgDesign2) as the generative engine and AbsciBind as the scoring/filtering engine.
  • ABS-201 (Androgenetic Alopecia) An AI-designed anti-prolactin receptor (PRLR) monoclonal antibody for the treatment of androgenetic alopecia (AGA). Demonstrated superior hair regrowth versus minoxidil in preclinical studies, with a Phase 1/2a HEADLINE trial initiated in December 2025. Estimated half-life of at least 65 days supports 2-3 doses over six months.
  • ABS-201 (Endometriosis) Indication expansion of ABS-201 anti-PRLR antibody for endometriosis as a non-sex-steroid hormonal therapeutic. Preclinical data demonstrated significant reductions in both spontaneous and evoked pain behaviors and suppression of inflammatory cytokines. Phase 2 trial targeted to initiate in Q4 2026.
  • ABS-202 A second anti-PRLR antibody in preclinical development targeting an inflammation and immunology indication, announced in 2026 as part of Absci's expanded prolactin program portfolio.
  • Reverse Immunology (AI Target Discovery) AI-enabled approach for novel therapeutic target discovery that identifies antibodies from patient samples of super immune responders, reconstructs fully human antibody sequences in silico, and pairs them with target antigens for AI optimization and IND-enabling studies.

Quantifiable outcome

  • AI-designed antibodies validated from concept to clinical trial pipeline in ~24 months
  • +7 more outcomes

Companies that use Absci

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Absci technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature9 records

Absci partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

  • Oracle Cloud InfrastructurecoreTechnology or Integration · 12 September 2025Collaboration to accelerate generative AI-driven drug discovery using OCI AI infrastructure and AMD GPUs. Enables Absci to consolidate infrastructure, reduce inter-GPU latency to 2.5 microseconds, and scale large-scale molecular-dynamics simulations.
  • AlmirallmajorStrategic or Co-development Partner · 2 September 2025Expanded collaboration to accelerate AI-powered drug discovery for skin diseases. Almirall's Karl Ziegelbauer stated: 'Almirall chose Absci because their de novo platform brings truly novel innovation to the industry's most challenging targets with high unmet medical need.'
  • Memorial Sloan Kettering Cancer CentermajorStrategic or Co-development Partner · 12 August 2024AI antibody generator collaboration for cancer research. Absci inks cancer collaboration with Memorial Sloan Kettering for AI-designed antibody therapeutics in oncology.
  • AstraZenecacoreStrategic or Co-development Partner · 4 December 2023$247M AI-enabled oncology antibody design pact. Absci applies its de novo AI antibody creation platform to design potential new antibody therapy in oncology. AstraZeneca's Puja Spara stated: 'This collaboration is an exciting opportunity to utilize Absci's de novo AI antibody creation platform to design a potential new antibody therapy in oncology.'
  • Merck (MSD)coreStrategic or Co-development Partner · 7 January 2022$610M biobucks drug discovery partnership (potential milestones and royalties). Merck Global Health Innovation Fund's Prem Tumkosit noted Absci falls into 'Next Horizon' technologies with potential to disrupt biopharma industry.
  • AMDcoreTechnology or IntegrationAMD invested in Absci and partnered to scale AI drug discovery using AMD Instinct MI355X GPUs. Mark Papermaster (CTO at AMD) stated: 'We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics.'
  • NVIDIAmajorTechnology or IntegrationNVIDIA powers Absci's in silico technologies. Kimberly Powell (VP Healthcare at NVIDIA) stated: 'Absci's powerful data generation and AI protein engineering platform is already helping the drug discovery industry, and NVIDIA is excited to help power and scale Absci's in silico technologies to achieve the best positive impact.'
  • OwkinmajorStrategic or Co-development PartnerCo-development partnership for immuno-oncology candidates. Owkin's Thomas Clozel (CEO) stated: 'This partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin's AI agents that can identify and experimentally validate novel therapeutic targets with Absci's pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.'
  • PrecisionLifemajorStrategic or Co-development PartnerR&D partnership combining leading generative AI approaches with PrecisionLife's unique disease biology insights. Steve Gardner (CEO of PrecisionLife) stated: 'Our partnership demonstrates the transformational innovation potential of coupling leading generative AI approaches with PrecisionLife's unique disease biology insights.'
  • CaltechmajorStrategic or Co-development PartnerHIV vaccine research collaboration funded by Bill & Melinda Gates Foundation. Absci designs antibody or antibody-like protein to bind to conserved HIV target exposed during cell infection process, in partnership with Caltech researchers.
  • InvetxminorStrategic or Co-development PartnerPartnership for innovative specialty therapeutics for companion animals. Juergen Horn (President of Invetx) stated: 'We selected Absci for this collaboration because of their leading platform for generative AI design of human antibodies.'
  • Oxford UniversityminorStrategic or Co-development PartnerAcademic partnership for AI-driven biological research and antibody development

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Absci competitors and assessment

Company assessment

Direct peers

  • Generate Biomedicines: Generate Biomedicines is a generative AI biology company designing de novo protein therapeutics, directly comparable to Absci's Origin-1 and Integrated Drug Creation Platform. Both compete for large-pharma partnership deals centered on AI-designed antibodies and novel biologics.
  • AbCellera Biologics: AbCellera is a public antibody discovery platform that combines high-throughput wet lab screening with machine learning to identify lead candidates for pharma partners. It competes head-to-head with Absci's SoluPro/ACE Assay stack and is similarly partnered with major pharmaceutical companies.
  • BigHat Biosciences: BigHat Biosciences uses AI/ML-guided antibody design with an integrated wet lab loop, mirroring Absci's lab-in-the-loop approach. Both target the same customer base (pharma seeking AI-designed antibody leads) and compete on cycle time, developability, and success rates.
  • Insilico Medicine: Insilico Medicine operates an AI-driven drug discovery platform that combines generative chemistry, target identification, and clinical development. While broader in modality than Absci, it is a directly comparable AI biotech pursuing pharma partnerships and an internal pipeline.
  • Recursion Pharmaceuticals: Recursion is a publicly traded AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Like Absci, it pursues both a partnership model and an internal pipeline, and competes for similar pharma and investor mindshare.
  • Schrödinger: Schrödinger provides computational chemistry and physics-based software for drug discovery, serving many of the same pharmaceutical customers as Absci. It is comparable as a public, platform-oriented AI-for-drug-discovery company monetized through software and partnerships.
  • Adimab: Adimab operates a proprietary antibody discovery and optimization platform serving pharma and biotech partners. It is directly comparable to Absci's antibody discovery and lead-optimization offering and competes for similar partnership economics.

Broad incumbents

  • Isomorphic Labs: Isomorphic Labs is Alphabet's commercial AI drug discovery business, applying DeepMind's protein-structure and generative modeling to pharma partnerships. As a deep-pocketed incumbent with overlapping capability to Absci's Origin-1, it is the most consequential broad competitor in the AI biologics design space.

Emerging players

  • Cradle Bio: Cradle is an AI protein engineering platform that uses generative models to help partners design improved proteins, including antibodies and enzymes. It overlaps with Absci's generative biology capabilities and targets a similar partner base, with a narrower focus on protein design.
  • EvolutionaryScale: EvolutionaryScale is an AI protein design company developing frontier generative models for protein engineering. While earlier-stage and more research-oriented, it competes for the same AI-for-proteins narrative and could attract comparable pharma collaborations in the longer term.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Absci social profiles

Digital presence

Absci financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Absci leadership team

Management profile

Number of profiles

Profiles20 records

Absci funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Absci M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Absci

What does Absci do?

Absci operates an Integrated Drug Creation Platform that combines generative AI models with proprietary high-throughput wet lab validation (SoluPro synthetic biology and ACE Assay) to enable de novo antibody design, multi-parametric lead optimization, and novel target discovery via reverse immunology. The platform serves pharmaceutical and biotech partners through drug creation collaborations structured with upfront payments, R&D funding, milestone payments, and royalties, while Absci simultaneously develops an internal pipeline of AI-designed therapeutics including ABS-201 (anti-PRLR antibody for androgenetic alopecia and endometriosis) and ABS-202.

Is Absci a public or private company?

Absci is a public company. It is classified as public and is currently operating.

When was Absci founded?

Absci was founded in 2011. It employs 101 to 250 people.

Where is Absci based?

Absci is headquartered in Vancouver, United States, in the North America region.

How does Absci make money?

Three revenue lines are on record. Partnership/Collaboration Revenue is the primary driver. The others are equity Financing and internal Pipeline Development.

Who are Absci's main competitors?

Direct peers on record are Generate Biomedicines, AbCellera Biologics, BigHat Biosciences, Insilico Medicine, Recursion Pharmaceuticals, Schrödinger and Adimab. Isomorphic Labs is listed as a broad incumbent. Emerging players are Cradle Bio and EvolutionaryScale.

Does Absci have an API?

No public API is recorded for Absci.

What industry is Absci in?

Absci's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewABSI: December brings the interim hair-loss readout; 26-week data are planned for 2027Absci Corporation expects a 92-day interim readout in December for its prolactin receptor-targeting hair-loss program, with 26-week data planned for 2027. Management sees a potential U.S. market above $25B and plans to start an endometriosis study in mid-2027.Simply Wall StAbsci Stock In Focus After Commercial Chief Hire And Shelf FilingAbsci reported a Q3 2026 net loss of $33.3 million and appointed Gerry Muhle as Chief Commercial Officer. The company filed a shelf registration for equity and debt to fund ABS-201 development. Analysts project revenue of $31.9 million and earnings of $5.1 million by 2029.Seeking AlphaAbsci anticipates interim 13-week ABS-201 pattern hair loss data next month as it plans mid-2027 endometriosis Phase 2 startAbsci's Q3 2026 earnings call said it will share interim 13-week data from the ABS-201 pattern hair loss trial next month, with full 26-week data early next year. The company moved its endometriosis Phase 2 start to mid-2027 and hired its first Chief Commercial Officer. Cash and equivalents stood at $173.7 million as of September 30, 2026.The Motley FoolAbsci (ABSI) Q3 2026 Earnings Call TranscriptAbsci reported Q3 2026 revenue of $304 million, down from $378 million a year earlier, and a net loss of $33.3 million. The company held $173.7 million in cash, expecting to fund operations into the second half of 2028. It plans to share interim 13-week pattern hair loss data in December 2026 and initiate a Phase 2 endometriosis trial in mid-2027.The Motley FoolAbsci (ABSI) Q3 2026 Earnings Call TranscriptAbsci reported Q3 2026 revenue of $304 million, down from $378 million a year earlier, and a net loss of $33.3 million. The company held $173.7 million in cash, expecting to fund operations into the second half of 2028. It plans to share interim 13-week pattern hair loss data in December 2026 and initiate a Phase 2 endometriosis trial in mid-2027.TradingViewABSI: ABS-201 readouts lead the outlook, with cash projected to fund operations into H2 2028Absci Corporation reported Q3 2026 R&D expense of $23.6 million and held $173.7 million in cash and marketable securities. The company projects these funds will support operations into the second half of 2028, with interim and full PHL data expected by December 2026 and early 2027, and a storyline endometriosis phase II planned for mid-2027.Investing.comEarnings call transcript: Absci Q3 2026 revenue miss weighs on sharesAbsci reported Q3 2026 revenue of $304,000, missing estimates by 56%, while adjusted EPS of -$0.19 was essentially in line with expectations. The revenue miss drove a 7.26% pre-market stock decline. Management expects 13-week proof-of-concept data for ABS-201 in December 2026.BenzingaAbsci Q3 2026 Earnings Call Transcript - Absci (NASDAQ:ABSI)Absci reported Q3 2026 results with R&D expenses of $23.6 million and SG&A of $9 million. The company plans to release interim 13-week proof-of-concept data for ABS201 in pattern hair loss next month, with full 26-week data early next year. It also intends to start a Phase 2 endometriosis trial by mid-2027.MarketScreenerAbsci Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Absci Corporation reported a Q3 net loss of $33.3 million, up from $28.71 million a year ago, and a nine-month net loss of $96.11 million, up from $85.62 million. Basic and diluted loss per share from continuing operations were $0.19 and $0.19 for Q3, and $0.60 and $0.60 for nine months, compared to $0.20 and $0.20 for Q3 and $0.65 and $0.65 for nine months.